ESC 365 - Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

ESC Premium Access

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Session: Abstract Programme

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor Y. Huo (Beijing, CN)

Event: ESC Asia with APSC & AFC 2020

Congress Presentation

Add to my library

About the speaker

Professor Yong Huo

Peking University First Hospital, Beijing (China)

0 follower

238 more presentations in this session

2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.

Speaker: Doctor D. Pol (Melbourne, AU)

3D right ventricular ejection fraction and longitudinal strain are independent predictors of major adverse cardiovascular events in patients with rrhythmogenic right ventricular cardiomyopathy

Speaker: Assistant Professor L. Hosseini (Bojnurd, IR)

A novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves

Speaker: Doctor A. Snir (Sydney, AU)

A novel therapeutic approach for coronary inflammation and lymphatic vessels using non-invasive low-intensity pulsed ultrasound in a porcine model with DES-induced coronary hyperconstricting responses

Speaker: Doctor T. Watanabe (Sendai, JP)

A real-world comparison of outcomes between fractional flow reserve-guided versus angiography-guided percutaneous coronary intervention

Speaker: Doctor C. Wong (Sydney, AU)

Access the full session

Abstract Programme

Speakers: Professor Y. Huo, Doctor D. Pol, Assistant Professor L. Hosseini, Doctor A. Snir, Doctor T. Watanabe...

About the event

ESC Asia with APSC & AFC 2020

3 December - 5 December 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources